Stock chart
Analyses on Epitomee (4)
- March 22, 2026March 22, 2026
- Follow-up
Epitome: How Much Is the Drug-Delivery Platform Really Worth at This Stage?
Epitome's drug-delivery platform is no longer just a concept, but at this stage it still belongs mainly in option value. There is preclinical data, a funded work plan and defined milestones, but no human trial, no binding partner, no active regulatory path and no revenue.
- Follow-up
Epitome: Can Europe Move from Approval to Repeat Orders?
Epitome's European story has moved from approval to order intake, but not yet to repeatability. The German order proves there is initial demand after approval, yet without a quarterly backlog split and without evidence of recurring shipments, 2026 still looks mainly like a comme…
- Follow-up
Epitome: How Much Real Runway Does the Cash Balance Still Provide?
Epitome still has cash, but less time than the year-end cash line alone suggests. On an all-in basis, after operating burn, lease cash and CAPEX, the runway already looks like a relatively short execution window in which commercialization has to start carrying part of the model.
Epitome Medical: Europe Is Open, But Orders and Cash Are Only Now Facing the Real Test
Epitome enters 2026 with its main regulatory hurdle largely behind it, but with the commercial and cash hurdle still open. Europe approval and the Germany order are real positive signals, yet the 2025 revenue base still rests on a single sale while all-in cash burn remains high.
